日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

奥拉帕尼治疗转移性去势抵抗性前列腺癌且通过循环肿瘤DNA检测发现存在BRCA1、BRCA2或ATM基因改变的患者的疗效

Matsubara, Nobuaki; de Bono, Johann; Olmos, David; Procopio, Giuseppe; Kawakami, Satoru; Ürün, Yüksel; van Alphen, Robbert; Flechon, Aude; Carducci, Michael A; Choi, Young Deuk; Hotte, Sebastien J; Korbenfeld, Ernesto; Kramer, Gero; Agarwal, Neeraj; Chi, Kim N; Dearden, Simon; Gresty, Christopher; Kang, Jinyu; Poehlein, Christian; Harrington, Elizabeth A; Hussain, Maha

Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma

前列腺特异性膜抗原靶向放射性核素诊疗技术应用于转移性透明细胞肾癌的理论依据

Giraudet, Anne Laure; Vinceneux, Armelle; Pretet, Valentin; Paquet, Emilie; Lajusticia, Alicia Sanchez; Khayi, Fouzi; Badel, Jean Noël; Boyle, Helen; Flechon, Aude; Kryza, David

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

高危冒烟型骨髓瘤患者免疫治疗反应的免疫生物标志物

Romanos Sklavenitis-Pistofidis ,Michelle P Aranha ,Robert A Redd ,Joanna Baginska ,Nicholas J Haradhvala ,Margaret Hallisey ,Ankit K Dutta ,Alexandra Savell ,Shohreh Varmeh ,Daniel Heilpern-Mallory ,Sylvia Ujwary ,Oksana Zavidij ,Francois Aguet ,Nang K Su ,Elizabeth D Lightbody ,Mark Bustoros ,Sabrin Tahri ,Tarek H Mouhieddine ,Ting Wu ,Lea Flechon ,Shankara Anand ,Jacalyn M Rosenblatt ,Jeffrey Zonder ,James J Vredenburgh ,Adam Boruchov ,Manisha Bhutani ,Saad Z Usmani ,Jeffrey Matous ,Andrew J Yee ,Andrzej Jakubowiak ,Jacob Laubach ,Salomon Manier ,Omar Nadeem ,Paul Richardson ,Ashraf Z Badros ,Maria-Victoria Mateos ,Lorenzo Trippa ,Gad Getz ,Irene M Ghobrial

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

免疫检查点抑制剂治疗首发癌症与第二原发癌症发生率降低相关。

Heudel, P; Chabaud, S; Perol, D; Flechon, A; Fayette, J; Combemale, P; Tredan, O; Desseigne, F; de la Fouchardiere, C; Boyle, H; Perol, M; Bachelot, T; Cassier, P; Avrillon, V; Terret, C; Michallet, A-S; Neidhardt-Berard, E-M; Nicolas-Virelizier, E; Dufresne, A; Belhabri, A; Brahmi, M; Lebras, L; Nicolini, F; Sarabi, M; Rey, P; Bonneville-Levard, A; Rochefort, P; Provensal, A-M; Eberst, L; Assaad, S; Swalduz, A; Saintigny, P; Toussaint, P; Guillermin, Y; Castets, M; Coutzac, C; Meeus, P; Dupré, A; Durand, T; Crochet, H; Fervers, B; Gomez, F; Rivoire, M; Gregoire, V; Claude, L; Chassagne-Clement, C; Pilleul, F; Mognetti, T; Russias, B; Soubirou, J-L; Lasset, C; Chvetzoff, G; Mehlen, P; Beaupère, S; Zrounba, P; Ray-Coquard, I; Blay, J-Y

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?

PSMA靶向治疗在转移性去势抵抗性前列腺癌中的应用:我们现在处于什么阶段,未来将走向何方?

Giraudet, Anne-Laure; Kryza, David; Hofman, Michael; Moreau, Aurélie; Fizazi, Karim; Flechon, Aude; Hicks, Rodney J; Tran, Ben

Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

针对复发性晚期生殖细胞肿瘤患者,采用TI-CE高剂量化疗联合卡铂治疗药物监测的多中心II期试验

Chevreau, Christine; Massard, Christophe; Flechon, Aude; Delva, Rémy; Gravis, Gwenaëlle; Lotz, Jean-Pierre; Bay, Jacques-Olivier; Gross-Goupil, Marine; Fizazi, Karim; Mourey, Loïc; Paci, Angelo; Guitton, Jérôme; Thomas, Fabienne; Lelièvre, Bénédicte; Ciccolini, Joseph; Moeung, Sotheara; Gallois, Yohan; Olivier, Pascale; Culine, Stéphane; Filleron, Thomas; Chatelut, Etienne

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy

一项随机、双盲、安慰剂对照的II期研究,旨在评估tasquinimod维持治疗对一线多西他赛化疗有反应或病情稳定的转移性去势抵抗性前列腺癌患者的疗效。

Fizazi, K; Ulys, A; Sengeløv, L; Moe, M; Ladoire, S; Thiery-Vuillemin, A; Flechon, A; Guida, A; Bellmunt, J; Climent, M A; Chowdhury, S; Dumez, H; Matouskova, M; Penel, N; Liutkauskiene, S; Stachurski, L; Sternberg, C N; Baton, F; Germann, N; Daugaard, G

Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)

长春氟宁-吉西他滨与长春氟宁-卡铂作为不适合顺铂治疗的晚期尿路上皮癌患者的一线化疗:一项国际随机 II 期试验的结果 (JASINT1)

De Santis, M; Wiechno, P J; Bellmunt, J; Lucas, C; Su, W-C; Albiges, L; Lin, C-C; Senkus-Konefka, E; Flechon, A; Mourey, L; Necchi, A; Loidl, W C; Retz, M M; Vaissière, N; Culine, S

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group

生殖细胞肿瘤患者脑转移:预后因素和治疗方案——来自全球生殖细胞癌组的分析

Feldman, Darren R; Lorch, Anja; Kramar, Andrew; Albany, Costantine; Einhorn, Lawrence H; Giannatempo, Patrizia; Necchi, Andrea; Flechon, Aude; Boyle, Helen; Chung, Peter; Huddart, Robert A; Bokemeyer, Carsten; Tryakin, Alexey; Sava, Teodoro; Winquist, Eric William; De Giorgi, Ugo; Aparicio, Jorge; Sweeney, Christopher J; Cohn Cedermark, Gabriella; Beyer, Jörg; Powles, Thomas

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value

编码蛋白酪氨酸激酶靶基因的增益和损失总和可预测对多激酶抑制剂治疗的反应:表征、验证和预后价值

Xiaojun Jiang, Daniel Pissaloux, Christelle De La Fouchardiere, Françoise Desseigne, Qing Wang, Valery Attignon, Marie-Eve Fondrevelle, Arnaud De La Fouchardiere, Maurice Perol, Philippe Cassier, Christelle Seigne, David Perol, Isabelle Ray-Coquard, Pierre Meeus, Jerome Fayette, Aude Flechon, Axel L